Texas AG Demands COVID-19 Vax Makers Produce Evidence on Safety & Efficacy
State Attorney Generals have led the way on many COVID-19-related freedom issues, including a response to President Joe Biden’s COVID-19 vaccine mandate for companies with 100 or more employees. A group of state AGs challenged and took the mandate to the Supreme Court. The High Court’s decision that the OSHA large-employer vaccine mandate was unlawful was the work of these AGs, as well as other parties opposing COVID-19 vaccine mandates. As noted by Tennessee’s AG, many states came forward to challenge the OSHA mandate. ------------------------------------ Join The Conversation! | https://trialsitenews.com/ ... https://www.youtube.com/watch?v=L9cPF5wtBV8
We delve into the recent legal battle between the U.S. Department of Justice (DOJ) and the state of Oklahoma over House Bill 4156 (HB 4156). Signed by Governor Kevin Stitt on April 30, 2024, this new state law imposes criminal penalties on individuals residing in Oklahoma without legal immigration status. The DOJ has filed a lawsuit challenging the constitutionality of this legislation, arguing that it is preempted by federal law and violates the U.S. Constitution.
House Bill 4156 creates a new crime called "impermissible occupation," making it a misdemeanor for a first offense and a felony for subsequent offenses. Those convicted are required to leave the state within 72 hours of their release from custody or face additional prosecution.
...
https://www.youtube.com/watch?v=r6zfU6ApEm4
#MedinCell’s Mission for ‘Mass Roll-out’ of #Ivermectin for COVID-19: Early Study Data Points Reveal Promise:
TrialSite News first introduced Montpellier, France-based MedinCell, and their efforts to commercialize an ivermectin-based treatment for COVID-19 back in April. The French biotech company now reports positive first results from a clinical trial aiming at the validating the safety of continuous administration of ivermectin. Presented at an international “Collaborative Workshop—Ivermectin against COVID-19,” MedinCell reports no side effects observed with the first two doses in the study, which totals three doses. And so, they announced via press release that a first long-acting injectable formulation is ready to enter regulatory development. Embracing a prophylactic strategy, the company seeks to mimic the approach taken against HIV: “preexposure prophylaxis” (PrEP) evidencing efficacy as well as the need for long-acting injectable treatments, as the are the only ones that guarantee the continuity of protection. This French company also explores a “postexposure prophylaxis” (PEP) effort for established close contact with COVID-19.
https://trialsitenews.com/medincells-mission-for-mass-roll-out-of-ivermectin-for-covid-19-early-study-data-points-reveal-promise/
Real-World Retrospective Exposure-Crossover Study of 70K+ Patients Reveals Most Frequent Complications Associated with COVID-19:
A sizable retrospective study involving the University of Buffalo, Aetion, Inc., HealthVerity, Inc. and the University of Toronto confirms a significant number of complications associated with COVID-19. Published in the Canadian Medical Association Journal (CMAJ), the team used de-identified outpatient and inpatient medical claims from American health databases to identify 70,288 patients who were infected with SARS-CoV-2, the virus behind COVID-19. Covering a duration from March 1 to April 30, 2020 over half of the health visits involved hospitalization, with about 5% of the total admitted into intensive care. With a median age of 65 and 55.8% female the authors studied a plethora of medical codes targeting those that increased in number post pandemic onset. Sure enough this real world evidence (RWE)-based study found that the most frequent complications associated with COVID-19 included pneumonia, respiratory failure, kidney failure and sepsis or systemic inflammation. These findings aligned with other observations. Overall, the risk associated with a patient with COVID-19 succumbing to these more serious ailments equaled 27.6% for pneumonia, 22.6% for respiratory failure, 11.8% kidney failure and 10.4% associated with sepsis or systemic inflammation.
Additionally these researchers found other real world evidence, although rare in associa
...
https://www.youtube.com/watch?v=flZWI3dbXRE
Join The Conversation! | https://trialsitenews.com/
Story 1 | Mexico City Wide Innovative Population-Level Study Administers Ivermectin-based Home Kits with Drastic Reduction in Hospitalizations
Since December 28, the ivermectin-based medical kits were distributed to mild to moderate symptomatic patients. The Mexico City Government sought to measure the effectiveness o f this population-wide intervention inclusive of the ivermectin-based medical kit in overall hospitalization during the pandemic. Using a quasi-experimental research design involving a Coarsened Exact Matching method leveraging hospital and phone call monitoring data, the study team estimated logistic-regression models with a range of observational data and found a significant reduction in hospitalizations among the cohort receiving ivermectin-based medical kit.
Story Article:
https://trialsitenews.com/mexico-city-wide-innovative-population-level-study-administers-ivermectin-based-home-kits-with-drastic-reduction-in-hospitalizations/
Story 2 | Uttar Pradesh Health Officials on Record: Claims Ivermectin as Prophylactic Has Lowered COVID-19 Infection Rate & Death Rate
The government of Uttar Pradesh, the most populated state in India, has declared that the use of Ivermectin as a “Prophylactic and therapeutic” has not only lowered transmission and infection rates but has also served to reduce the COVID-19 death rate as well. It’s been a year since the first cluster of five (5) cases was reported in Agra, and recently, the Health Department has shared positive results with the ongoing program. TrialSite shared August last year that the most populated Indian state embraced Ivermectin as a COVID-19 therapy and prophylactic while no Western press bothered to touch the subject. More recently, TrialSite reported that ivermectin has been included in the national COVID-19 guidance due in part to positive outcomes now emerging. Again, there hasn’t been a peep from the West. Uttar Pradesh was an early mover, embracing a protocol using both the anti-parasite drug as well as Doxycycline for use as a prophylactic and as a therapeutic tool targeting COVID-19. Clinical trials in Bangladesh using a similar protocol were producing results last summer as well. Now the Uttar Pradesh health department shared recently that it also plans on conducting a controlled study once this second wave of the pandemic wanes.
Story Article:
https://trialsitenews.com/uttar-pradesh-health-officials-on-record-ivermectin-as-prophylactic-has-lowered-covid-19-infection-rate-death-rates/
...
https://www.youtube.com/watch?v=YnNchHI5H3o
Former CNN political analyst Chris Cillizza predicts Republicans have a 99.9% chance of winning US Senate if Trump wins in November. With Trump raising $400 million since his conviction and several Democratic seats at risk, the political landscape is shifting dramatically towards the right.
...
https://www.youtube.com/watch?v=ltm58amJdmw
Join The Conversation! | https://trialsitenews.com/
Dr. Kevin Murphy discusses PrTMS and how it is used to treat a wide variety of neurological, mental & physical health issues.
https://www.prtms.com/
...
https://www.youtube.com/watch?v=Lj6VitKGJF4
Welcome to TrialSite News on YouTube. Join the Conversation! Visit us at: https://trialsitenews.com/
Are you looking to get transparent, honest, and open clinical news? If so you've come to the right place. Our goal is to talk to you, the patient, the doctor, the CRO, the pharmaceutical investigator, all of you, with candor and honesty.
If you want to stay in the know please subscribe to our YouTube channel and ring the bell to be notified, or you can subscribe to our newsletter which you can find, at trialsitenews.com
If you're looking to advertise on any of our platforms please reach out to us directly, the email is in the about section.
Thank you for watching, we appreciate each and every one of you in our audience!
...
https://www.youtube.com/watch?v=ao-3NrSky7I
Welcome to another episode of the Watchlist Series. Today, we take a look at #IL6Inhibitors, and whether or not, they are the right class of biologic to be testing on #COVID19 Patients.
#Regeneron and Sanofi announced that the U.S. Phase 3 clinical trial of #Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation failed to meet its primary and key secondary endpoints when the drug was added to best supportive care compared to best supportive care alone (placebo). In the primary analysis group, adverse events were experienced by 80% of Kevzara patients and 77% of placebo patients. Serious adverse events that occurred in at least 3% of patients and more frequently among Kevzara patients included multi-organ dysfunction syndrome (6% Kevzara, 5% placebo) and hypotension (4% Kevzara and 3% placebo). The industry sponsors have halted this U.S.-based clinical trial, including a second cohort of patients who received a higher dose of Kevzara (800 mg), based on these findings. Both Regeneron and Sanofi have commented in a press release to submit detailed peer-reviewed disclosure of what happened in this partially publicly financed clinical trial. There are several other Kevzara studies ongoing involving COVID-19 patients: what are the implications of the results from those studies? What about the 43 Actemra (tocilizumab) clinical trials associated with COVID-19 patients and the failed Italian tocilizumab (Actemra) study? Is their growing evidence that pharma company’s pursuit of repurposing IL-6 inhibitors against COVID-19 is a failed strategy? After all, clinical trials are expensive and, as is the case in this U.S., study public funds can be involved. How can these funds be best utilized to protect patients?
https://www.trialsitenews.com/does-kevzara-failure-in-covid-19-patients-requiring-mechanical-ventilation-implicate-other-repurposed-autoimmune-drugs-in-the-war-on-covid-19/
...
https://www.youtube.com/watch?v=gf_oY1WmYZM
Potential Game Changer: Operation Warp Speed Gains Momentum:
#OperationWarpSpeed represents an impressive collaborative effort among federal government authority, agencies and initiatives that have an aggressive set of targets, including a safety and effective #vaccine by January 2021. Never before would a vaccine be developed at such speed, hence the term “warp” borrowed from Captain James T. Kirk’s Starship Enterprise.
https://www.trialsitenews.com/potential-game-changer-operation-warp-speed-gains-momentum/
AND
Pressure for a COVID-19 Vaccine by U.S. Election; Traditional Vaccine Platforms Left Out of “Operation Warp Speed”
A June 22nd article from The Guardian looks at whether the FDA is under pressure to approve a vaccine prior to the November U.S. election. According to their article, The context for this includes FDA’s recent revocation of the EUA for #Hydroxychloroquine. Other symptoms of pressure include early approval of ineffective antibody tests and the FDA’s, “tight rein on private lab testing” up to March 13. “The worry here is that they will use the [EUA] standard” to approve a vaccine, according to , a medical professor at the University of Pennsylvania and former Obama White House health policy adviser. Emanuel is concerned that a poor vaccine would cause folks to ignore social distancing and face covering rules.
https://www.trialsitenews.com/pressure-for-a-covid-19-vaccine-by-u-s-election-traditional-vaccine-platforms-left-out-of-operation-warp-speed/
...
https://www.youtube.com/watch?v=pqlfJb31Uis
The world’s focus on China because of the Covid pandemic has not been a welcome event for the Asian nation, striving to become the number one economy and world power. Reports out of China claimed the country was overwhelmed with the epidemic, news the Chinese sought to suppress. Now, a press freedom group is reporting China is the biggest global jailer of journalists, with over 100 reporters currently behind bars. The group, Reporters Without Borders, claims China’s leader, Xi Jingping is conducting a “crusade against journalism”. It appears, the Chinese government is moving to “control the narrative”.
------------------------------------
Join The Conversation! | https://trialsitenews.com/
...
https://www.youtube.com/watch?v=fY_UN6VoOrw